Ben Myers!

January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for

Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics " Tim Dyer is the Co-Founder and CEO of Addex Therapeutics , which is focusing

Ben Myers!

Tim Dyer , CEO, Roger Mills , CMO and Robert Lütjens , Head of Discovery Biology, will provide a business

strategic priorities, including pursuing additional collaborations across our portfolio,” said Tim Dyer

Starting from a high-throughput screening hit, we describe the iterative optimization of a chemical series

Complexes Industry News Mavorixafor reduces infection rates among patients with WHIM syndrome Bristol Myers

This week's highlight includes congrats to: Madison Walker , Benjamin Myers , et al., for their research

GPCR Binders, Drugs, and more Inhibiting a promiscuous GPCR: iterative discovery of bitter taste receptor

the present as prologue Industry News Exscientia Business Update for Third Quarter 2023 Addex CEO Tim Dyer

Ben Myers and Dr. Niña Caculitan.

controls midgut development in Drosophila Karuna Therapeutics announces that is now part of Bristol Myers

Industry News Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta

which have an established role in chemokine gradients and oligomerization (Deshauer C et al. 2015; Dyer